MIAMI, Aug. 24, 2026 /PRNewswire/ — BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, is entering the clinic next quarter. BreakBio aims to be not first-in-class but best-in-class. It is designed for both higher efficacy than Moderna or BioNTech and it is also designed to treat more cancer indications than Moderna or BioNTech.
BreakBio, the Third Player in Personalized Drugs, Enters the Clinic
BreakBio is designed for higher efficacy than Moderna’s individualized neoantigen therapy (INT). Higher efficacy because BreakBio is designed to find better targets per patient. It is an AI first biotech company. For every patient, its platform integrates highest quality tumor DNA sequencing, RNA sequencing, mass-spectrometry-based immunopeptidomics (of that patient) with proprietary deep AI analysis to find better targets on that patient’s cancer cells. Better targets means killing more (or all) of the cancer cells.BreakBio is designed to extend personalized drugs to more cancer indications than Moderna. BreakBio achieves this by targeting not just neoantigens (associated with mutations as Moderna and BioNTech do) but it also searches for and finds, in each patient, some of the hundreds of cancer-associated non-mutated proteins such as cancer testis antigens, embryonic antigens, etc. – so BreakBio is designed to also work for low mutational cancers, which means it is designed to work for all solid cancers both high mutational cancers like melanoma and low mutational cancers like colorectal.
About BreakBio:
BreakBio is a new generation of personalized cancer drugs designed to deliver both greater efficacy per patient and treat a broader range of cancers than today’s individualized neoantigen therapy competitor. The company combines mass spectrometry, machine learning, and its proprietary AI platform to design and manufacture individualized peptide-based medicines tailored to each patient’s cancer and combines them with approved cancer therapies to drive deeper and more durable anti-tumor responses.
Unlike approaches focused only on mutation-related neoantigen targets found in high-mutational cancers like melanoma, BreakBio targets neoantigens, but also targets non-mutated antigens (found by its AI platform per patient) in order to broaden the treatment to all solid tumors.
Media Contact:
Kim Nancarrow
COO/CFO
BreakBio Corp.
info@breakbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/breakbio-the-third-player-in-personalized-drugs-enters-the-clinic-302858746.html
SOURCE BreakBio Corp.
